NO20073876L - Pyrazolopyrimidinderivater som mGluR2-antagonister - Google Patents

Pyrazolopyrimidinderivater som mGluR2-antagonister

Info

Publication number
NO20073876L
NO20073876L NO20073876A NO20073876A NO20073876L NO 20073876 L NO20073876 L NO 20073876L NO 20073876 A NO20073876 A NO 20073876A NO 20073876 A NO20073876 A NO 20073876A NO 20073876 L NO20073876 L NO 20073876L
Authority
NO
Norway
Prior art keywords
pyrazolopyrimidine derivatives
derivatives
mglur2 antagonists
preparation
treatment
Prior art date
Application number
NO20073876A
Other languages
English (en)
Norwegian (no)
Inventor
Erwin Goetschi
Silvia Gatti Mcarthur
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20073876L publication Critical patent/NO20073876L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20073876A 2005-02-11 2007-07-24 Pyrazolopyrimidinderivater som mGluR2-antagonister NO20073876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101027 2005-02-11
PCT/EP2006/000940 WO2006084634A1 (en) 2005-02-11 2006-02-03 Pyrazolo-pyrimidine derivatives as mglur2 antagonists

Publications (1)

Publication Number Publication Date
NO20073876L true NO20073876L (no) 2007-09-10

Family

ID=36090752

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073876A NO20073876L (no) 2005-02-11 2007-07-24 Pyrazolopyrimidinderivater som mGluR2-antagonister

Country Status (18)

Country Link
US (1) US7361659B2 (de)
EP (1) EP1851225B1 (de)
JP (1) JP4708438B2 (de)
KR (1) KR100968291B1 (de)
CN (1) CN101115755B (de)
AR (1) AR052568A1 (de)
AT (1) ATE512966T1 (de)
AU (1) AU2006212457B2 (de)
BR (1) BRPI0607927A2 (de)
CA (1) CA2597608C (de)
ES (1) ES2365406T3 (de)
IL (1) IL184712A (de)
MX (1) MX2007009106A (de)
NO (1) NO20073876L (de)
RU (1) RU2402553C2 (de)
TW (1) TW200716120A (de)
WO (1) WO2006084634A1 (de)
ZA (1) ZA200706353B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085398A1 (de) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
EP2268645B1 (de) * 2008-03-06 2014-11-12 Sanofi Substituierte dihydro-, trihydro- und tetrahydrocycloalkyloxazolopyrimidinone, verfahren und verwendung als allosterische mglur modulatoren
US8207181B2 (en) 2008-03-06 2012-06-26 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
KR20140077963A (ko) * 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
EP2666775A1 (de) 2012-05-21 2013-11-27 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
HK1206615A1 (en) 2012-10-23 2016-01-15 霍夫曼-拉罗奇有限公司 Mglu2/3 antagonists for the treatment of autistic disorders
MX2016013711A (es) 2014-04-23 2017-01-13 Hoffmann La Roche Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (de) 2014-09-26 2016-03-30 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3215511B1 (de) 2014-11-06 2024-04-17 Bial-R&D Investments, S.A. Substituierte pyrazolo(1,5-a)pyrimidine und deren verwendung bei der behandlung von medizinischen störungen
AU2015357169B2 (en) 2014-12-03 2021-03-04 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
EA037941B1 (ru) 2015-12-18 2021-06-09 Янссен Фармацевтика Нв ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
MX388912B (es) 2016-04-06 2025-03-20 Lysosomal Therapeutics Inc Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
KR20180133461A (ko) * 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2018127207A1 (zh) * 2017-01-09 2018-07-12 南京明德新药研发股份有限公司 噻唑衍生物及其应用
MY201041A (en) 2017-11-24 2024-01-31 Sumitomo Pharma Co Ltd Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group ii metabotropic glutamate receptor
WO2020007355A1 (zh) * 2018-07-06 2020-01-09 南京明德新药研发有限公司 噻唑类化合物的晶型及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168237T3 (es) 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
DK0891978T3 (da) 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
EP1379511B1 (de) * 2001-04-12 2005-07-20 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
JP2006523707A (ja) * 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
ATE383361T1 (de) * 2004-06-21 2008-01-15 Hoffmann La Roche Pyrrazolopyrimidinderivate

Also Published As

Publication number Publication date
RU2007128624A (ru) 2009-03-20
KR20070104592A (ko) 2007-10-26
TW200716120A (en) 2007-05-01
ES2365406T3 (es) 2011-10-04
EP1851225B1 (de) 2011-06-15
EP1851225A1 (de) 2007-11-07
AR052568A1 (es) 2007-03-21
RU2402553C2 (ru) 2010-10-27
JP4708438B2 (ja) 2011-06-22
IL184712A0 (en) 2007-12-03
IL184712A (en) 2013-05-30
ZA200706353B (en) 2009-09-30
CN101115755B (zh) 2013-01-16
AU2006212457A1 (en) 2006-08-17
CA2597608A1 (en) 2006-08-17
BRPI0607927A2 (pt) 2009-10-20
KR100968291B1 (ko) 2010-07-07
JP2008530042A (ja) 2008-08-07
US7361659B2 (en) 2008-04-22
AU2006212457B2 (en) 2011-04-14
MX2007009106A (es) 2007-09-11
WO2006084634A1 (en) 2006-08-17
US20060183756A1 (en) 2006-08-17
CN101115755A (zh) 2008-01-30
ATE512966T1 (de) 2011-07-15
CA2597608C (en) 2013-12-24

Similar Documents

Publication Publication Date Title
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20092342L (no) Azaspiroderivativater
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20045301L (no) Substituert 1,3-diphenylprop-2-en-1-one derivat, fremstilling og anvendelse derav.
NO20070339L (no) 1-aza-bicyklo[3 3.1]nonaner
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
TW200716120A (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20071703L (no) Kinazolinderivater
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application